Neuraxis, Inc. NRXS 深 沪
已收盘 08-01 16:00:00 美东时间
2.50
-0.120
-4.58%
华盛通- 最 高2.62
- 今 开2.62
- 成交量 1.27万股
- 最 低 2.50
- 昨 收 2.62
- 总市值 1803.98万
- 52周最高 6.20
- 市盈率 静 --
- 换手率 0.18%
- 52周最低 1.33
- 委 比 0.00%
- 总股本 721.59万
- 历史最高 6.93
- 量 比 0.26
- 振 幅 4.58%
- 历史最低 1.33
- 每 手 1
- 风险率 0.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NeurAxis, Inc. Ends Agreement with Masimo Corporation
NeurAxis, Inc. ( ($NRXS) ) has provided an announcement. On July 1, 2025, NeurA...
07-04 01:47
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives
NeurAxis, Inc. announced medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, across two health insurers in Connecticut and Massachusetts, covering approximately 700,000 members. This brings nationwide coverage for PENFS to roughly 53 million. IB-Stim, an FDA-cleared, non-surgical device for functional abdominal pain associated with irritable bowel syndrome (IBS) and pediatric functional dys...
06-17 12:00
美股大行评级 | 超配！Hinge Health获多家大行首予评级； Oppenheimer上调Mate目标价从665美元升至775美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1141651881139785729.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持SurgePays Inc(SURG)"买入"评级，目标价从8.75美元升至9美元</p> <p>• Ascendiant Capital：维持LiqTech Internatio
06-17 09:46
NeurAxis Says Proprietary PENFS Technology Officially Incorporated Into Newly Released Clinical Practice Guidelines Issued By Pediatric Academic Society For Treatment Of FAP In IBS
Practice guidelines published in the Journal of Pediatric Gastroenterology & Nutrition (JPGN) name Percutaneous Electrical Nerve Field Stimulation (PENFS) as a recommended treatment option for FAP in IBSNeurAxis's
06-10 20:03
NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS
NeurAxis’s Percutaneous Electrical Nerve Field Stimulation (PENFS) technology has been incorporated into clinical guidelines for Functional Abdominal Pain (FAP) in Irritable Bowel Syndrome (IBS), making it the only FDA-cleared pediatric treatment. This inclusion is expected to drive widespread insurance coverage and accelerate growth for the company’s IB-Stim product, targeting the multi-billion-dollar market for FAP treatment.
06-10 12:00
NeurAxis, Inc. Releases Investor Presentation
An announcement from NeurAxis, Inc. ( ($NRXS) ) is now available. On May 23, 20...
05-29 04:56
NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
NeurAxis, Inc. will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference on May 29, 2025. The webcast begins at 9:30 a.m. ET and can be accessed via the provided links. NeurAxis focuses on neuromodulation therapies, including its FDA-cleared IB-Stim™ for functional abdominal pain in adolescents with IBS. Additional clinical trials are ongoing. For more information...
05-27 12:00
NeurAxis, Inc. Announces $5 Million Stock Offering
The latest update is out from NeurAxis, Inc. ( ($NRXS) ). On May 20, 2025, Neur...
05-22 19:17
NeurAxis, Inc. Receives $1 Million from Warrant Exercises
NeurAxis, Inc. ( ($NRXS) ) just unveiled an announcement. NeurAxis, Inc. has re...
05-22 05:48
NeurAxis slides 21%, raises $5M via stock
NeurAxis (NYSE:NRXS) entered into definitive agreements for the purchase and sale of an aggregate of ~1.54M shares of its common stock at a purchase price of $3.25 per share in a registered direct o...
05-21 19:28
